Literature DB >> 23381983

Clinical experience in invasive fungal infections: multiple fungal infection as the first presentation of HIV.

Claudia Mihon1, Teresa Alexandre, Aida Pereira.   

Abstract

Fungal infections constitute an important cause of morbidity and mortality in HIV-infected patients. The authors describe the case of a 40-year-old healthy male patient with a 2-month history of fever, shivers, asthenia and anorexia, who had lost weight during the past 6 months. Laboratory investigations revealed a positive HIV screening. Computed tomography scans of the chest and abdomen showed thoracic and lumbo-aortic adenopathies. Cryptococcus neoformans was isolated from cultures of blood, bone marrow, cerebrospinal fluid and from material obtained by transbronchial biopsy. Moreover, Cryptococcus spp. were seen in the lymph node biopsy. Pneumocystis jirovecii was isolated from bronchoalveolar lavage, whereas Aspergillus fumigatus and Aspergillus flavus were detected in material from a transbronchial biopsy. The patient initially received treatment with sulfamethoxazole plus trimethoprim and amphotericin B, which resulted in a substantial clinical improvement. After the diagnosis of invasive aspergillosis, amphotericin B was replaced by voriconazole as antifungal therapy and antiretroviral therapy was added. The simultaneous occurrence of three different infectious diseases-disseminated cryptococcosis, invasive pulmonary aspergillosis and Pneumocystis jirovecii pneumonitis-in a HIV-infected patient is extremely rare and there is no doubt that both early diagnosis and treatment are crucial for the patient's chances of survival.

Entities:  

Mesh:

Year:  2013        PMID: 23381983     DOI: 10.1007/s40261-012-0019-z

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  4 in total

Review 1.  Treatment options of invasive fungal infections in adults.

Authors:  Ursula Flückiger; Oscar Marchetti; Jacques Bille; Philippe Eggimann; Stefan Zimmerli; Alexander Imhof; Jorge Garbino; Christian Ruef; Didier Pittet; Martin Täuber; Michel Glauser; Thierry Calandra
Journal:  Swiss Med Wkly       Date:  2006-07-22       Impact factor: 2.193

2.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

Authors:  Raoul Herbrecht; David W Denning; Thomas F Patterson; John E Bennett; Reginald E Greene; Jörg-W Oestmann; Winfried V Kern; Kieren A Marr; Patricia Ribaud; Olivier Lortholary; Richard Sylvester; Robert H Rubin; John R Wingard; Paul Stark; Christine Durand; Denis Caillot; Eckhard Thiel; Pranatharthi H Chandrasekar; Michael R Hodges; Haran T Schlamm; Peter F Troke; Ben de Pauw
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

3.  [Antifungal combination therapy in invasive fungal infections].

Authors:  J Gellen-Dautremer; F Lanternier; E Dannaoui; O Lortholary
Journal:  Rev Med Interne       Date:  2009-09-19       Impact factor: 0.728

4.  Long-term suppressive therapy for pulmonary aspergilloma in an immunocompromised man with AIDS. Is it always necessary?

Authors:  K Yoganathan
Journal:  Int J STD AIDS       Date:  2009-06       Impact factor: 1.359

  4 in total
  2 in total

1.  Gastrointestinal cryptococcoma - Immune reconstitution inflammatory syndrome or cryptococcal relapse in a patient with AIDS?

Authors:  Abdu K Musubire; David B Meya; Robert Lukande; Andrew Kambugu; Paul R Bohjanen; David R Boulware
Journal:  Med Mycol Case Rep       Date:  2015-03-26

2.  Multiple fungal infection in a patient on chronic low dose corticotherapy.

Authors:  Shiho Yamazato; Noriaki Nakai; Norito Katoh
Journal:  Indian J Dermatol       Date:  2014-11       Impact factor: 1.494

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.